LIFE - aTyr Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
94
0
0
-
-
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
14,410
20,385
30,067
42,846
34,504
Selling General and Administrative
9,842
12,435
17,078
15,094
13,112
Total Operating Expenses
24,252
32,820
47,145
57,940
47,616
Operating Income or Loss
-24,158
-32,820
-47,145
-57,940
-47,616
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-1,263
-1,695
-1,062
-29
-357
Income Before Tax
-25,421
-34,515
-48,207
-57,904
-47,973
Income Tax Expense
-
0
-
-49
-
Income from Continuing Operations
-25,421
-34,515
-48,207
-57,855
-47,973
Net Income
-25,421
-34,515
-48,207
-57,855
-47,973
Net Income available to common shareholders
-25,421
-34,515
-48,207
-57,855
-47,988
Reported EPS
Basic
-
-16.10
-26.18
-34.16
-42.42
Diluted
-
-16.10
-26.18
-34.16
-42.42
Weighted average shares outstanding
Basic
-
2,140
1,843
1,692
1,131
Diluted
-
2,140
1,843
1,692
1,131
EBITDA
-
-32,820
-47,145
-57,940
-47,616